CLORGILINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H15Cl2NO.ClH
Molecular Weight	308.631
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CN(CCCOC1=C(Cl)C=C(Cl)C=C1)CC#C

InChI

InChIKey=BBAZDLONIUABKI-UHFFFAOYSA-N

InChI=1S/C13H15Cl2NO.ClH/c1-3-7-16(2)8-4-9-17-13-6-5-11(14)10-12(13)15;/h1,5-6,10H,4,7-9H2,2H3;1H

HIDE SMILES / InChI

Description
Sources: https://www.drugbank.ca/drugs/DB04017 | https://www.ncbi.nlm.nih.gov/pubmed/9564606 | https://www.ncbi.nlm.nih.gov/pubmed/24040395 | https://www.ncbi.nlm.nih.gov/pubmed/6342562 | https://www.ncbi.nlm.nih.gov/pubmed/20060423 | https://www.ncbi.nlm.nih.gov/pubmed/12652347

Clorgiline is a monoamine oxidase (MAO) inhibitor. Specifically, it is an irreversible and selective inhibitor of MAO-A. Clorgiline was under investigation for antidepressant and anxiolytic potential but has never been marketed, likely due to efficacy concerns. It continues to see routine use as a molecular probe in biomedical research examining a number of neurological disease and cancer models. In addition to inhibiting the MAO-A receptor, it has also been found to bind to the sigma1 receptor, and with high affinity to the I2 imidazoline receptor.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Amine oxidase [flavin-containing] A 14 Target ID: P21397 Gene ID: 4128.0 Gene Symbol: MAOA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564606	Inhibitor 8297	1.4 nM [IC50]
Sigma non-opioid intracellular receptor 1 26 Target ID: Q99720\|\|\|Q7Z653 Gene ID: 10280.0 Gene Symbol: SIGMAR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20060423	Binding Agent 1064
Nischarin 7 Target ID: Q9Y2I1\|\|\|Q9UFW3 Gene ID: 11188.0 Gene Symbol: NISCH Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12652347	Binding Agent 1064
Monoamine oxidase A 49 Target ID: CHEMBL1951 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564606 \| https://www.medchemexpress.com/Clorgiline-hydrochloride.html	Inhibitor 8297	1.4 nM [IC50]
Sigma non-opioid intracellular receptor 1 26 Target ID: Q99720\|\|\|Q7Z653 Gene ID: 10280.0 Gene Symbol: SIGMAR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20060423	Binding Agent 1064
Nischarin 7 Target ID: Q9Y2I1\|\|\|Q9UFW3 Gene ID: 11188.0 Gene Symbol: NISCH Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12652347	Binding Agent 1064

Conditions

Condition	Modality	Highest Phase	Product
Depression 235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564606	Primary	Not Provided 504	Unknown Approved Use Unknown
Cancer 592 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24040395 https://www.ncbi.nlm.nih.gov/pubmed/25152370	Primary	Basic research	Unknown Approved Use Unknown
Obsessive-compulsive disorder 28 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6342562	Primary	Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Possible development of the serotonin syndrome in man.	1982 Jul	7091416
Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients.	1982 May	7092487
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.	1987 Sep	3670563
Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).	1998	9564606
Effects of elevated serotonin levels on patterns of GAP-43 expression during barrel development in rat somatosensory cortex.	2002 Dec 15	12480131
Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats.	2006 Dec	17229101
Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.	2011 Dec 22	22023459
Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.	2011 Oct 27	21923181
Piperine potentiates the antidepressant-like effect of trans-resveratrol: involvement of monoaminergic system.	2013 Dec	23943324
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.	2015 Jan 5	25455453

Patents

Sample Use Guides

In Vivo Use Guide

Patients suffering depression were administered 30 mg/day of Clorgyline for three or more weeks. However, this regime produced negligible changes in trace amine excretion including, phenylethylamine, para-tyramine, and meta-tyramine.

Route of Administration: Unknown

In Vitro Use Guide

T24, HCT116, and HL60 cells were incubated overnight and treated with 1 micro-, 0.3 µM or 0.1 µM of 5-Aza-CdR, respectively for 24 hours. After removal of 5-Aza-CdR, cells were treated with 10 µM clorgyline every day for 21 days. Multiple doses of clorgyline were tested: 1 µM, 10 µM, and 100 µM. Clorgyline was found to impair cell growth in a dose-dependent manner and the optimal dose was identified as 10 microM.

Name

Type

Language

CLORGILINE HYDROCHLORIDE

Common Name

English

N-(3-(2,4-DICHLOROPHENOXY)PROPYL)-N-METHYL-2-PROPYNYLAMINE HYDROCHLORIDE

Systematic Name

English

2-PROPYN-1-AMINE, N-(3-(2,4-DICHLOROPHENOXY)PROPYL)-N-METHYL-, HYDROCHLORIDE (1:1)

Systematic Name

English

CLORGYLINE HYDROCHLORIDE

Common Name

English

NSC-759306

Code

English

Code System Code Type Description

ECHA (EC/EINECS)

241-760-5